BioNTech Faces Fresh Patent Offensive as Arbutus Channels Moderna Settlement into New UPC Cases
Published on 07/18/2026 at 14:02 | Redaktion boerse-global.de
The legal battles enveloping the mRNA vaccine landscape have escalated sharply, with Arbutus Biopharma and its partner Genevant lodging three additional international lawsuits against Pfizer and BioNTech. Two of those complaints were filed before the Unified Patent Court under case numbers PR-UPC-CFI-0002562/2026 and PR-UPC-CFI-0002566/2026, targeting European patents EP 4 241 767 and EP 4 495 237. A third action was brought in Canada. The move comes barely a week after Arbutus collected roughly $178 million from a settlement with Moderna on 8 July 2026 — fresh firepower it is now directing at the makers of Comirnaty.
Compounding the pressure, Sanofi waded into the mRNA patent fray on 14 July with two separate lawsuits filed in the U.S. District Court of New Jersey. Rather than going after BioNTech directly, Sanofi has taken aim at Pfizer over Comirnaty and at Moderna over Spikevax and mNexspike, asserting eight patents against Pfizer and ten against Moderna. The claims, inherited from its $3.2 billion acquisition of Translate Bio in 2021, cover mRNA purification methods and encapsulation in lipid nanoparticles — the same core technology at the heart of the Arbutus actions. Notably, Sanofi is not seeking an injunction, only what it calls "reasonable compensation."
The stock itself has absorbed the news with minimal volatility. BioNTech shares closed the week at €80.20, edging up 0.06% on Friday — a reading that lines up closely with the €80.00 close cited in earlier trading sessions, where the day's gain was 0.69%. Either way, the price remains stuck in a well-defined rut: 24% below the 52-week high of €105.80 set in January and 5.8% beneath the 200-day moving average of €84.90. The 50-day average sits at €79.23, just under the current level, offering a thin layer of near-term support. The relative strength index of 49.3 points to a market that is neither stretched to the upside nor oversold — a portrait of indecision.
Should investors sell immediately? Or is it worth buying BioNTech?
While the courtroom drama unfolds, the shareholder register is telling a different story — one of shifting conviction among institutional investors. During the second quarter of 2026, several asset managers increased their exposure. The DZ BANK expanded its BioNTech holding by 2.9%, Russell Investments Group added significantly, and Natixis established a new position. Wall Street Zen upgraded its rating to "Hold." Yet against that backdrop, Cathie Wood’s ARK ETF sold its entire BioNTech stake in the week ending 8 July, creating a clear directional divergence between the banking sector and one of the most closely followed active fund managers.
For investors trying to gauge where BioNTech goes from here, the tape sends conflicting signals. The year-to-date decline sits at 1.41%, while the 12-month loss is a steeper 16.28% — a reminder that the longer-term trend remains downward despite the recent sideways churn. Adding to the uncertainty, Arbutus has not only armed itself with litigation cash but also announced plans to return up to $230 million to its own shareholders through buybacks starting in the third quarter, plus an expected dividend from Genevant. That financial muscle could give Arbutus considerable leverage in any settlement talks.
Each new lawsuit — whether from Arbutus, Genevant, or Sanofi — chips away at the assumption that BioNTech’s royalty and licensing exposure is contained. The Moderna-Arbutus settlement provided a rough benchmark for what a similar resolution might cost Pfizer and BioNTech, though no concrete liabilities have been recognized yet. Sanofi’s decision to forgo an injunction suggests a willingness to monetise rather than block, which could actually narrow the range of outcomes. For now, the stock is caught between the gravitational pull of the 200-day average above and the modest uptick in institutional buying below — a tug-of-war that the next few weeks of court activity and third-quarter flows may finally resolve.
Ad
BioNTech Stock: New Analysis - 18 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
